Fundraisings and IPOs

* On June 16, 2015, Biotie Therapies announced that it has today closed its U.S. public offering. As previously announced, the Company offered 3,806,047 ADSs in its U.S. public offering at a price to the public of $14.888 per ADS for gross proceeds of $56,664,427.73 (€50,238,875.55 at the fixed ECB exchange rate of $1.1279 per euro as at June 10, 2015). This includes the full exercise of the underwriters\' over-allotment option. In addition, the underwriters have purchased 519,583 ADSs from UCB S.A. at the U.S. public offering price. Biotie will not receive any proceeds from the ADSs sold by UCB S.A. Following the completion of the U.S. public offering the automatic conversion of the convertible notes issued by the Company to certain U.S. investors and existing shareholders on May 28, 2015 and the issue of 220,400,001 new shares to such noteholders at the pre-determined conversion price of €0.15 per new share has also been effected.

The new shares issued by the Company in the U.S. public offering (including the over-allotment option) and due to the automatic conversion of the notes have been registered with the Finnish Trade Register and will be admitted to trading on NASDAQ OMX Helsinki Ltd. on or about June 17, 2015. Following the registration of the new shares with the Finnish Trade Register, the total number of shares and votes in the Company amounts to 980,851,935.

* On June 11, 2015, Biotie Therapies announced that it has completed the pricing of its U.S. public offering of 3,761,418 ADSs at a price to the public of $14.888 per ADS for gross proceeds of $55,999,991.18 (€49,649,783.83 at the fixed ECB exchange rate of $1.1279 per euro as at June 10, 2015). The share to ADS ratio is 80 to one, and the ADSs will represent 300,913,440 newly issued shares in the Company with a subscription price of €0.165 per new share (at the above mentioned fixed exchange rate). In addition, Biotie has granted the underwriters an option to subscribe for up to an additional 44,629 ADSs representing up to 3,570,320 newly issued shares in the Company, and UCB S.A. has granted the underwriters an option to purchase up to 519,583 ADSs, within 30 days of this offering solely to cover over-allotments. Biotie will not receive any proceeds from the ADSs sold by UCB S.A. The issuance of new shares by the Company for the purpose of the completion of the U.S. public offering and the Over-allotment Option are based on the authorization granted by the Annual General Meeting of shareholders on May 26, 2015.

* On June 8, 2015, Biotie Therapies announced it has decided to increase its proposed U.S. public offering from $50 million to $56 million American Depositary Shares representing its shares. The Company announced on June 4, 2015 its proposed U.S. public offering of $50 million. UCB has since agreed to cover the majority of the underwriters\' 30-day option to subscribe for up to an additional 15% of the shares represented by ADSs sold in the U.S. public offering for the sole purpose of covering potential over-allotments. As a result, the Company has decided to increase the offering to $56 million, based on the authorization granted by the Annual General Meeting of shareholders on May 26, 2015. UCB\'s shares represent 519,583 ADS out of the potential maximum of 566,688 ADS based on the below prices and assumptions. Biotie will not receive any proceeds from the UCB shares and there will be no change in the number of newly registered shares as a result of the sale of these UCB shares. =

* On June 4, 2015, Biotie Therapies announced that the company has commenced the marketing of a proposed U.S. public offering of $50 million American Depositary Shares representing its shares, based on the authorization granted by the Annual General Meeting of shareholders on May 26, 2015. On June 2, 2015, the last reported sale price of Biotie\'s shares on the NASDAQ OMX Helsinki Ltd. was €0.168 per share, which is equivalent to a price of $14.82 per ADS. The offering is expected to be completed by the end of June.

* On May 14, 2015,  Biotie Therapies Corp has filed a registration statement on Form F-1 with the U.S. Securities and Exchange Commission relating to its proposed U.S. public offering of American Depositary Shares, representing Biotie\'s ordinary shares. The number of ADSs to be offered and the price range for the offering have not yet been determined. Biotie has made an initial submission to list its ADSs on the NASDAQ Global Market under the ticker symbol \"BITI\". RBC Capital Markets and Stifel are acting as joint book-running managers. JMP Securities is acting as lead manager and Roth Capital Partners is acting as a co-manager.